Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 17/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14999167 | 1.00 | EP300 (0.83) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL29441235 | 0.91 | EP300 (1.00) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL14991292 | 0.91 | EP300 (1.00) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL12092858 | 0.91 | EP300 (1.00) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL29711734 | 0.91 | EP300 (1.00) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL14991291 | 0.91 | EP300 (1.00) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL26157789 | 0.91 | EP300 (0.87) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL14991408 | 0.90 | EP300 (0.83) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL14991407 | 0.90 | EP300 (0.83) | EP300CREBBPMEN1KMT2AUSP2 | |
| SCHEMBL15003843 | 0.90 | EP300 (0.83) | EP300CREBBPMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011085039-A2 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |